Iron overload treatment and quality of life in Greece
Part of Blood & lymphatic, Genetic & congenital, Hormones & metabolism clinical trials.
This trial looks at people with chronic iron overload caused by blood disorders like thalassemia. It tests a medication called deferasirox to see how it affects their quality of life.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older
- You have a blood disorder (like thalassemia) that causes iron buildup from blood transfusions
- You are already taking deferasirox and need at least 900 mg daily
- Your doctors can check your medical records from the last 6 months
- You agree to follow the study procedures
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This early-phase trial studies HGI-002 to see if it’s safe and can help people with severe alpha thalassemia who need frequent blood transfusions. It also requires planning for a special treatment approach that includes busulfan pre-treatment and stem cell transplantation.
This study checks how well children with beta thalassemia stick to their daily oral chelation pill (deferasirox). It aims to find ways to help them take it more regularly, improving iron control and reducing complications.
This trial tests whether a higher or lower dose of iron works better for people on peritoneal dialysis who have low iron levels. It aims to find the best way to treat iron deficiency in this group.
This study tests whether intravenous (IV) iron therapy can help older adults who have heart failure with preserved pumping function and low iron levels. It aims to improve symptoms and quality of life.
This Phase 2 study tests SP-420 to help people with transfusion-related iron overload from either beta-thalassemia or low-risk myelodysplastic syndromes. It aims to see if the treatment can improve how the body handles excess iron, which builds up after repeated transfusions.
This Phase 2 trial tests whether giving deferiprone (an “iron-chelator,” meaning it helps remove excess iron) guided by cardiac MRI can improve outcomes after an acute anterior heart attack. It aims to study safety and benefit for people who can undergo MRI with contrast and meet specific heart, kidney, liver, and blood criteria.
Hear when a new Thalassemia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.